Hui Qin Wang
Overview
Explore the profile of Hui Qin Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Molony R, Funk T, Trabucco G, Corcoran E, Ruddy D, Varadarajan M, et al.
Front Immunol
. 2022 Aug;
13:909979.
PMID: 35990699
CD3-engaging bispecific antibodies (BsAbs) enable the formation of an immune synapse between T cells and tumor cells, resulting in robust target cell killing not dependent on a preexisting tumor specific...
2.
Lee E, Szvetecz S, Polli R, Grauel A, Chen J, Judge J, et al.
Sci Rep
. 2021 Jul;
11(1):14841.
PMID: 34290299
High-grade serous ovarian cancers (HGSOC) represent the most common subtype of ovarian malignancies. Due to the frequency of late-stage diagnosis and high rates of recurrence following standard of care treatments,...
3.
Wang H, Mulford I, Sharp F, Liang J, Kurtulus S, Trabucco G, et al.
Cancer Res
. 2021 Jan;
81(11):3079-3091.
PMID: 33504557
p53 is a transcription factor that plays a central role in guarding the genomic stability of cells through cell-cycle arrest or induction of apoptosis. However, the effects of p53 in...
4.
Monaco K, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, et al.
Clin Cancer Res
. 2020 Dec;
27(7):2061-2073.
PMID: 33355204
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled...
5.
Baltschukat S, Engstler B, Huang A, Hao H, Tam A, Wang H, et al.
Clin Cancer Res
. 2019 Jan;
25(10):3164-3175.
PMID: 30674502
Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical trials, both as a single agent and in combination. Here, we describe the preclinical data of capmatinib, which...
6.
Dardaei L, Wang H, Singh M, Fordjour P, Shaw K, Yoda S, et al.
Nat Med
. 2018 Mar;
24(4):512-517.
PMID: 29505033
Most anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung tumors initially respond to small-molecule ALK inhibitors, but drug resistance often develops. Of tumors that develop resistance to highly potent second-generation ALK inhibitors,...
7.
Wang H, Halilovic E, Li X, Liang J, Cao Y, Rakiec D, et al.
Elife
. 2017 Apr;
6.
PMID: 28425916
The efficacy of ALK inhibitors in patients with -mutant neuroblastoma is limited, highlighting the need to improve their effectiveness in these patients. To this end, we sought to develop a...
8.
Gao H, Korn J, Ferretti S, Monahan J, Wang Y, Singh M, et al.
Nat Med
. 2015 Oct;
21(11):1318-25.
PMID: 26479923
Profiling candidate therapeutics with limited cancer models during preclinical development hinders predictions of clinical efficacy and identifying factors that underlie heterogeneous patient responses for patient-selection strategies. We established ∼1,000 patient-derived...
9.
Wang H, Altomare D, Skele K, Poulikakos P, Kuhajda F, Di Cristofano A, et al.
Oncogene
. 2005 Apr;
24(22):3574-82.
PMID: 15806173
Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer. To explore a possible connection between AKT and FAS, immunohistochemical analyses were conducted...
10.
Altomare D, Wang H, Skele K, De Rienzo A, Klein-Szanto A, Godwin A, et al.
Oncogene
. 2004 Jun;
23(34):5853-7.
PMID: 15208673
Activation of the PI3K/AKT pathway may contribute to tumorigenesis. AKT mediates survival signals that protect cells from apoptosis and, thus, is a potentially important therapeutic target. To determine the frequency...